Global results validating AFP-L3, AFP and DCP using the GALAD model were presented at EASL 2015 meeting
During the EASL meeting in Vienna, April 22nd to 26th 2015, researchers from the University of Liverpool, UK, and the University of Turin, Italy, presented study results on the HCC biomarkers AFP-L3 and DCP. Both investigations included the GALAD model for improved hepatocellular carcinoma (HCC) risk determination.
Objective biomarker-based models for improved detection and prognosis assessment of HCC
Recently, researchers from the University of Birmingham and the University of Liverpool inthe United Kingdom, under the direction of Prof. Philip Johnson, published data on the GALAD model for hepatocellular carcinoma (HCC) risk determination and the BALAD-2 model for prognosis assessment. The biomarkers AFP, AFP-L3 and DCP are key components in both models.
Launch of HCC biomarkers AFP-L3 and DCP in Romania by Proton Impex 2000 S.r.l.
Proton Impex 2000 S.r.l. and Wako Chemicals GmbH signed an agreement for the distribution of the hepatocellular carcinoma (HCC) biomarkers AFP-L3 and DCP, as well as the microchip-based platform µTASWakoTM i30. The reference laboratory Lotus Medical in Bucharest will be the first laboratory to offer the biomarkers.
Lansarea biomarkerilor HCC AFP - L3 și DCP în România de către Proton Impex 2000 SRL
Proton Impex 2000 SRL şi Wako Chemicals GmbH au semnat un acord de distribuţie al biomarkerilor
HCC AFP - L3 şi DCP , prin intermediul platformei de ultima generatie μTASWakoTM i30. Laboratorul Lansarea biomarkerilor HCC AFP - L3 şi DCP în România de către Proton Impex 2000 SRL clinic Lotus Medical din Bucureşti este primul utilizator din Romania al acestui sistem performant.
HCC biomarkers AFP-L3 and DCP are now available at the University Hospital of Essen, Germany
The University Hospital of Essen signed an agreement with Wako Chemicals GmbH to provide the serum tests AFP-L3 and DCP in the central laboratory under the management of Dr. med. L. Volbracht. These innovative tests are now available for the Department of Gastroenterology and Hepatology, University Hospital of Essen, directed by Prof. Dr. med. G. Gerken to aid in the diagnosis of hepatocellular carcinoma (HCC).
Combination of biomarkers AFP and DCP is superior to AFP alone in detection of HCC
Prof. Schlaak and clinicians from the University Hospital Essen, Germany, demonstrate that the combined use of the serological biomarkers AFP and DCP could improve early detection of HCC.
Automated HA LT enables implementation of routine Hepascore calculation
Dr. Yagmur, Medical Care Centre Dr. Stein and colleagues, Moenchengladbach, and study partners of the University Hospital Aachen, Germany, presented results on the analytical evaluation of HA LT during the GASL congress 2013. How this enables the implementation of an automated Hepascore has been discussed.
Publication on AFP-L3% and DCP levels in cases with misleading AFP results from Greece
Clinicians of the Hippokration General Hospital in Athens, Greece, published data on the diagnostic performance of AFP-L3% and DCP in HCC patients with non-diagnostic AFP levels and non-HCC patients with elevated AFP levels.
Study results on serum hyaluronic acid (HA) presented during the annual meeting 2012 of the American Association for the Study of Liver Diseases (AASLD)
Prof. G. Papatheodoridis and other researchers from the Hippokration General Hospital and the Laboratory of Histology & Embryology of the University of Athens, Greece, presented study results on the liver fibrosis marker HA by two posters.